Filing Details
- Accession Number:
- 0001567619-22-000622
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-05 17:16:39
- Reporting Period:
- 2022-01-03
- Accepted Time:
- 2022-01-05 17:16:39
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1770787 | 10X Genomics Inc. | TXG | Laboratory Analytical Instruments (3826) | 455614458 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1786386 | J. Justin Mcanear | C/O 10X Genomics, Inc. 6230 Stoneridge Mall Road Pleasanton CA 94588 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Class A Common Stock | Acquisiton | 2022-01-03 | 10,000 | $5.04 | 48,819 | No | 4 | M | Direct | |
Class A Common Stock | Disposition | 2022-01-03 | 3,583 | $145.16 | 45,236 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2022-01-03 | 4,083 | $145.96 | 41,153 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2022-01-03 | 1,334 | $146.92 | 39,819 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2022-01-03 | 500 | $148.04 | 39,319 | No | 4 | S | Direct | |
Class A Common Stock | Disposition | 2022-01-03 | 500 | $149.18 | 38,819 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Class A Common Stock | Stock Option (right to buy) | Disposition | 2022-01-03 | 10,000 | $0.00 | 10,000 | $5.04 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
350,159 | 2028-11-02 | No | 4 | M | Direct |
Footnotes
- The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- This transaction was executed in multiple trades at prices ranging from $144.54 to $145.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $145.54 to $146.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $146.54 to $147.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $147.58 to $148.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This transaction was executed in multiple trades at prices ranging from $148.66 to $149.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- This option, originally for 600,000 shares, of which 249,841 shares have been exercised, vested as to 1/4th of the shares on October 8, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.